Flowonix Medical has received approval from the US Food and Drug Administration (FDA) for its new product, Patient Therapy Controller (PTC).
The PTC is said to interface with the firm’s Prometra platform of intrathecal infusion devices.
It is a small hand-held device with a touch-screen that allows the patient to start a bolus delivery of medication from the implanted pump.
Flowonix Medical president and CEO Steven Adler said: "Our new Patient Therapy Controller demonstrates our ongoing commitment to making the Prometra drug delivery system the most advanced infusion system available.
"This device will allow a great number of patients, specifically those with variable pain pathologies, to benefit from targeted drug delivery."
This year, Flowonix also obtained approval for three new products, including the targeted drug delivery device Prometra II.
The company first received FDA approval to market its Prometra in 2012.